Impact of TiO₂-free film coating composition on the dissolution of poorly soluble and poorly permeable drugs
DOI:
https://doi.org/10.12923/cipms-2026-0007Słowa kluczowe:
titanium dioxide, dissolution profile, pharmaceutical formulationAbstrakt
The growing interest in developing coatings for pharmaceutical products that are free of titanium dioxide (TiO₂) stems from concerns about potential health risks and resulting regulatory changes. Finding alternatives to TiO₂ is essential to meeting the requirements of the new guidelines. For generic drugs, maintaining compliance with the dissolution profiles of the reference drug is also important. This study evaluated the impact of different TiO₂-free coating formulations on the dissolution profiles and eligibility for a biological equivalence exemption of a BCS Class IV drug product in two strengths. Specifically, the study aimed to determine whether these coatings could replicate the dissolution profile of the reference product for the high-strength and meet the criteria for exemption from the bioequivalence requirement for the low strength. Tablet cores containing two BCS Class IV active ingredients were manufactured and coated with four different TiO₂-free coatings in two strengths. We evaluated the tablets' physical parameters and dissolution profiles. Similarity of the dissolution profiles was statistically evaluated in relation to the reference medicinal product and between different strengths. Different TiO₂-free coatings altered the dissolution profile of a BCS Class IV drug product depending on the testing environment. This variability suggests that some coatings may hinder dissolution, while others may facilitate it under certain conditions. These results underscore the importance of thoroughly testing different TiO₂-free coatings during the development of BCS Class IV drugs. The choice of coating should be tailored to the specific drug formulation and its intended use.
Bibliografia
1. Bischoff NS, de Kok TM, Sijm DTH, van Breda SG, Briedé JJ, Castenmiller JJM, et al. Possible adverse effects of food additive E171 (titanium dioxide) related to particle specific human toxicity, including the immune system. Int J Mol Sci. 2021;22(1):207. https://doi.org/10.3390/ijms22010207
2. Bettini S, BoutetRobinet E, Cartier C, Coméra C, Gaultier E, Dupuy J, et al. Foodgrade TiO₂ impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon. Sci Rep. 2017;7:40373. https://doi.org/10.1038/srep40373
3. Commission Regulation (EU) 2022/63 of 14 January 2022 Amending Annexes II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council as regards the food additive titanium dioxide (E171). Off J Eur Union. Accessed May 13, 2025. https://eur-lex.europa.eu/eli/reg/2022/63/oj
4. Palugan L, Spoldi M, Rizzuto F, Guerra N, Uboldi M, Cerea M, et al. What’s next in the use of opacifiers for cosmetic coatings of solid dosage forms? Insights on current titanium dioxide alternatives. Int J Pharm. 2022;616:121550. https://doi.org/10.1016/j.ijpharm. 2022.121550
5. Radtke J, Wiedey R, Kleinebudde P. Alternatives to titanium dioxide in tablet coating. Pharm Dev Technol. 2021;26(9):989-999. https://doi.org/10.1080/10837450.2021.1968900
6. European Medicines Agency. Guideline on the investigation of bio-equivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Corr. Published 2010.
Accessed May 13, 2025. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf
7. European Pharmacopoeia. 11th ed. European Directorate for the Quality of Medicines & Health Care; 2022.
8. European Medicines Agency. Clinical pharmacology and pharmacokinetics - Questions and answers. Updated 2022. Accessed May 13, 2025. https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers
9. Stern PW. Effects of film coatings on tablet hardness. J Pharm Sci. 1976;65(9):1291-1295. https://doi.org/10.1002/jps.2600650908
10. Patel NG, Banella S, Serajuddin ATM. Moisture sorption by polymeric excipients commonly used in amorphous solid dispersions and its effect on glass transition temperature: II. Cellulosic polymers. J Pharm Sci. 2022;111(11):3114-3129. https://doi.org/10.1016/j.xphs. 2022.07.020
11. Jang EH, Park YS, Choi DH. Investigation of the effects of materials and dry granulation process on the mirabegron tablet by integrated QbD approach with multivariate analysis. Powder Technol. 2021;382:23-39. https://doi.org/10.1016/j.powtec.2020.12.044
12. Jannin V, Duysburgh C, Gonzalez V, Govaert M, Agisson M, Marzorati M, et al. In vitro evaluation of the gastrointestinal delivery of acid-sensitive pancrelipase in a next generation enteric capsule using an exocrine pancreatic insufficiency disease model. Int J Pharm. 2023;630:122441. https://doi.org/10.1016/j.ijpharm.2022. 122441
13. Samuelov Y, Donbrow M, Friedman M. Sustained release of drugs from ethylcellulose-polyethylene glycol films and kinetics of drug release. J Pharm Sci. 1979;68(3):325-329. https://doi.org/10.1002/jps.2600680318
14. Suzzi D, Stefan R, Khinast JG. Local analysis of the tablet coating process: Impact of operation conditions on film quality. Chem Eng Sci. 2010;65:5699-5715. https://doi.org/10.1016/j.ces.2010.07.007
15. Xie C, You Y, Ma H, Zhang X, Li T, Liu Y, et al. Mechanism of inter-tablet coating variability: Investigation about the motion behavior of ellipsoidal tablets in a pan coater. Powder Technol. 2020. https://doi.org/10.1016/j.powtec.2020.10.088
Pobrania
Opublikowane
Numer
Dział
Licencja
Prawa autorskie (c) 2026 Piotr Adam Chodak, Renata Pawlak-Morka, Roberto Manganaro, Patrycja Stylska, Ewa Szymańska-Dębska (Autor)
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
